09:00 AM EDT, 08/05/2025 (MT Newswires) -- ImmunityBio ( IBRX ) reported a Q2 net loss Tuesday of $0.10 per diluted share, narrowing from a net loss of $0.20 a year earlier.

Analysts polled by FactSet expected a loss of $0.11.

Revenue for the quarter ended June 30 was $26.4 million, up from $1 million a year earlier.

Analysts surveyed by FactSet expected $23.1 million.

As of June 30, the company said it had $153.7 million in cash and or cash equivalents on hand.

The company's shares were up more than 1% in recent Tuesday premarket activity.